

## Index

### a

abdominal tuberculosis 105f.  
 acid-fast bacteria (AFB) 66  
 acquired immunodeficiency syndrome (AIDS)  
 116, 213f.  
 active tuberculosis  
 – case detection 7  
 – impact of DOTS on incidence 9  
 – treatment 7ff.  
 amikacin (AMK) 186  
 amoxicillin-clavulanic acid (AMX-CLV) 187,  
 188  
 amplified-fragment length polymorphism  
 (AFLP) 49  
 analytical tools 43  
 anemia 91  
 annual risk of tuberculosis infection (ARTI)  
 25f., 26f.  
 anorexia 105  
 antiretroviral (ARV) therapy 125  
 ascites 90, 98  
 aspirate 66

### b

BCG protection  
 – correlates of protection 258  
 – role of environmental mycobacteria 257  
 – role of helminth infections 257  
 – variation against pulmonary disease 257ff.  
 BCG strains  
 – genetic and phenotypic differences 254f.  
 – origins 253f.  
 – reactivity 255f.  
 BCG vaccination  
 – adverse events 250  
 – contraindications 252  
 – duration of efficacy 244  
 – efficacy against different TB forms 247

– efficacy of revaccination 249f.  
 – epidemiology 245ff.  
 – history 245f.  
 – immune responses 259  
 – immunology 245ff.  
 – mouse model 252f.  
 – non-specific effects 249  
 – proposed biological mechanisms 252  
 – route of vaccination 251  
 – vaccination schedules 250  
 – variations in BCG efficacy 248  
 bone tuberculosis 101f.  
 bronchoscopy 96

### c

capreomycin (CM) 186, 196  
 cavitation 71f., 110  
 cell-mediated immunity 252, 258  
 central nervous system (CNS) 72, 78,  
 187  
 central nervous system tuberculosis 103f.  
 cetyl pyridinium chloride (CPC) 37  
 chemotherapy 131ff.  
 – drugs 134  
 – principles 134  
 chest x-ray 71, 72  
 clarithromycin (CLR) 188  
 clinical diagnosis 63ff.  
 clinical trials 56  
 clofazimine (CFZ) 187  
 computed tomographic (CT) scans 102ff.  
 corticosteroids 197  
 culture 67  
 – liquid media 67f.  
 – solid media 68  
 cycloserine (CS) 187  
 cytochrome P450 (CYP protein) 215ff.  
 cetyl pyridinium bromide (CPB) 37

**d**

- death rate 12
- delayed-type hypersensitivity (DTH) 73, 259
- diagnostic algorithms 63ff.
- diarylquinoline 220
- direct repeat (DR) region 46f.
- direct variable repeat (DVR) 46
- directly observed treatment, short-course (DOTS) 1f., 118f., 137, 182f., 185, 199
- disseminated tuberculosis 109f.
- drug discovery 143
  - clinical development 155ff.
  - evolution 144f.
  - lead finding 150f.
  - lead optimization 151ff.
  - target finding 146ff.
- drug resistance 4, 11, 24, 33, 55, 143, 234
  - acquired resistance 234
  - primary resistance 234
- drug susceptibility testing (DST) 183ff., 195
- drugs 24, 56, 115, 137
  - biodistribution 150
  - classification 186
  - development 148
  - penetration 148, 152
  - properties 144
- drug treatment
  - access to treatment 123
  - effective treatment regimens 121
  - patients' rights and responsibilities 122
  - recommendations 134f.
  - response to treatment 123
  - risk of failure 138

**e**

- early secretory antigen target (ESAT)-6 proteins 74f., 157
- empyema 100
- enzyme-linked immunosorbent assay (ELISA) 74
- epidemic 41, 50ff.
- ethambutol (ETH) 135, 136, 140, 201, 213, 219
- ethionamid (ETA) 186, 203
- ethylenediamine 221
- exact tandem repeat (ETR) 44
- extensively drug-resistant tuberculosis (XDR-TB) 38, 182, 214f., 215, 218
- extrapulmonary tuberculosis 66, 97f., 119

**f**

- fluorescence amplified-length polymorphism (FAFLP) 49
- fluoroquinolones 191, 202, 219

**g**

- gatifloxacin 219
- gene expression profiling 153
- genetic fingerprint 42, 51
- genetic marker
  - evolution 51
- genitourinary tuberculosis 106f.
  - epidemiologic pattern 106
  - pathogenesis 106
- genotype 55
- genotyping methods 43ff., 52
- global tuberculosis control 115, 124
- granuloma 99, 108f., 152

**h**

- high resolution computed tomography (HRCT) 71f., 155f.
- high throughput screening (HTS) 146f., 150f.
- human immunodeficiency virus (HIV) 4ff., 17, 24, 28, 56, 66, 72, 90ff., 116, 134f., 168ff., 182f., 213ff.
  - epidemic 109
  - infection rates 5
  - tuberculosis co-infection 9, 11
- hyponatremia 91
- hypoxia 150, 153

**i**

- imaging mass spectrometry (IMS) 155
- immunodiagnosis 72
- individualized treatment regimens (ITRs) 188
- insertion sequences 47
- interferon (IFN)- $\gamma$  74f., 100, 157, 245
- interferon- $\gamma$  release assay (IGRA) 29, 75ff., 168
- isoniazid (INH) 4, 7, 133f., 143, 148, 175f., 181, 186, 196, 213, 219
- isoniazid preventive therapy (IPT) 7, 115f.

**j**

- joint tuberculosis 101f.

**k**

- kanamycin (KM) 186, 201
- Klebsiella pneumoniae* 94

**l**

- laboratory error 54
- latent *M. tuberculosis* infection (LTBI) 75, 185ff.
  - background 165
  - diagnosis 167ff.
  - epidemiology 169
  - incidence 171

- pathophysiology 165ff.
  - prevalence 170ff.
  - risk factors for reactivation 174
  - risk of reactivation 171ff.
  - treatment 7, 167f.
  - leukocytosis 110
  - leukopenia 91, 110
  - lipoarabinomannan (LAM) 157
  - lumbar puncture 103f.
  - lymph node 98, 105
  - lymph node tuberculosis 98
  - lymphadenitis 98f.
- m**
- magnetic resonance imaging (MRI) 72, 102
  - major polymorphic tandem repeat (MPTR) 43f.
  - marker 42f.
  - matrix-assisted-laser-desorption-ionization (MALDI) 155
  - meningitis 103f.
  - metronidazole 150
  - millennium development goal (MDG) 1, 11, 29, 38
  - minimum inhibitory concentration (MIC) 184, 187
  - mixed infection 54
  - mixed linker 48
  - models
    - areas of uncertainty 237f.
    - basic TB model 232
    - drug resistant TB 234
    - individual-based models 230
    - network models 230
    - simple compartmental models 228ff.
    - susceptible-infectious-removed (SIR) model 228ff.
    - TB/HIV model 234
  - molecular epidemiology 41ff.
    - application 51ff.
    - purpose 42
    - requirements for successful application 42
  - moxifloxacin 219
  - multidrug-resistant tuberculosis (MDR-TB) 2, 175, 189, 214, 220
    - clinical management 181ff.
    - diagnosis 183f.
    - epidemiology 181ff.
    - HIV 197
    - in pediatrics and obstetrics 194ff.
    - in pregnancy 195f.
  - multidrug-resistant tuberculosis (MDR-TB) treatment 181
    - case examples 182ff.
    - corticosteroids 197
    - first-line agents 190
    - individualized approaches 188f.
    - initial approach 189
    - parenteral agents 190
    - second-line agents 191
    - standardized approaches 188f.
    - surgery 197f.
    - treatment failure 192f.
  - mycobacterial growth indicator tube (MGIT) 69
  - mycobacterial interspersed repetitive unit (MIRU) 44ff., 70
  - mycobacterial interspersed repetitive unit variable number tandem repeats (MIRU-VNTR) 44ff., 70
  - Mycobacterium avium* 153
  - Mycobacterium avium* complex (MAC) 74
  - Mycobacterium bovis* bacillus Calmette-Guérin (BCG) 6, 17, 24f., 27, 46, 56, 73, 115, 117, 166ff.
  - Mycobacterium smegmatis* 106
  - Mycobacterium tuberculosis* 1, 24f., 41ff., 63ff.
    - clinical diagnosis 63ff.
    - population structure 51
  - Mycobacterium tuberculosis* complex 46, 67
- n**
- nearest genetic distance 51
  - necrosis 154
  - nitroimidazole 220
  - non-nucleoside reverse transcriptase inhibitor (NNRTI) 214, 216f.
  - non-synonymous single nucleotide polymorphism (nsSNP) 48
  - non-tuberculous mycobacteria (NTM) 67, 71ff.
  - nucleoside reverse transcriptase inhibitor (NRTI) 214, 216
- p**
- pericardial tuberculosis 107
  - pericarditis 107f.
  - peripheral blood mononuclear cells (PBMCs) 253, 256
  - peritonitis 105
  - phage test 69f.
  - pharmacokinetics (PK) 145
  - phenotype 55
  - pleural tuberculosis 99f.
  - pleuritis 99
  - polymerase chain reaction (PCR) 44, 64, 70f., 184
  - polymorphic GC-rich repetitive sequence (PGRS) 44f.

- positron emission tomography (PET) 155  
 preventive therapy 7  
 primary sampling unit (PSU) 30  
 Pro-Glu (PE) family 44  
 proof of concept studies 143ff.  
 proteome analysis 153  
 prothionamide (THA) 187  
 public health 155ff., 121  
 pulmonary tuberculosis 91ff., 101  
 – clinical features 89ff., 115  
 – diagnostic investigations 120  
 – medical history 92  
 – microbiological evaluation 96  
 – physical examination 92  
 – principles for treatment 134f.  
 – radiographic evaluation 92ff.  
 purified protein derivative (PPD) 25, 73f.,  
 167, 245  
 pyrazinamide (PZA) 133, 136, 140, 191, 213  
 pyrrole 221
- q**  
 quinolones 186
- r**  
 radiology 71f.  
 radiometric method 68  
 reactivation 52  
 recurrent tuberculosis 53  
 region of difference (RD) 74  
 repetitive sequences 43  
 restriction fragment length polymorphism  
 (RFLP) 44, 47ff.  
 rifampicin 4, 143, 174f., 200  
 rifampin (RIF) 133, 135f., 139, 181, 200,  
 213, 217
- s**  
 sample collection 65ff.  
 secondary sampling unit (SSU) 30  
 single nucleotide polymorphism (SNP) 46,  
 48f.  
 single-photon emission computed tomography  
 (SPECT) 155  
 skeletal tuberculosis 101  
 smear microscopy 66f.  
 spoligotyping 46f.  
 sputum 31, 65f.  
 standard uptake value 156  
 standardized treatment regimens  
 (STRs) 188f.  
*Staphylococcus aureus* 94  
 stop TB partnership 1ff., 29, 134  
 stop TB strategy 3, 7, 11, 13, 17, 125ff.  
 streptomycin (SM) 131f., 136, 140, 186  
 structure-activity relationship (SAR) 144f.,  
 150  
 surveillance for drug resistant tuberculosis  
 – goal 125, 126  
 – laboratory approach 36  
 – rationale 33  
 – sample selection 34  
 – targets 125, 126  
 surveillance of tuberculosis infection 24ff.  
 – alternative methods 29  
 – analysis 28  
 – calculation 28  
 – conducting the survey 28  
 – design 26  
 – difficulties in interpretation 27  
 – incidence of infection 27  
 – prevalence of infection 26f.  
 – rationale 24  
 – sample selection 26  
 – sample size 26  
 – standardization 25f.  
 surveillance studies 23ff.  
 surveys of tuberculosis disease 29ff.  
 – analysis 33  
 – case detection 7, 31  
 – chest x-ray screening 31  
 – conducting the survey 32  
 – rationale 29  
 – sample selection 30  
 – sputum culture 31  
 – sputum smear 31  
 – symptom screening 32  
 – tuberculin skin test 32  
 symptom screening 32
- t**  
 T-cell response 260f.  
 test units (TU) 73  
 thiacetazone (THZ) 187  
 transmission 52, 115, 227, 231, 237  
 – from smear negative cases 53  
 – physical measures to decrease  
 transmission 118  
 – risk factors 53  
 tuberculin skin test (TST) 25, 72ff., 166  
 – history 72  
 tuberculoma 103f.  
 tuberculosis (TB) 1ff., 41, 63, 143  
 – abdominal TB 105  
 – basic TB model 232  
 – bone TB 101f.  
 – case detection 118  
 – central nervous system TB 103

- chemotherapy 131ff.
- clinical features 89ff.
- control 1ff.
- development 23
- diagnosis 35, 89
- disease cycle 116
- disseminated TB 109
- drugs 131
- eliminating in the 21st century 13
- epidemic 5, 16
- extrapulmonary TB 97
- genitourinary TB 106f.
- global dynamics 3ff.
- global epidemiology 1ff.
- HIV coinfection 11
- incidence rate 4, 14
- joint TB 101f.
- lymph node TB 98
- manifestation 90
- natural history 231f.
- outbreaks 52
- pericardial TB 107
- population-level dynamics 231ff.
- pleural TB 99ff.
- prevention 25, 134
- pulmonary TB 91ff.
- reactivation 3
- recurrent tuberculosis 53
- regional dynamics 3
- renal TB 106
- skeletal TB 101
- symptoms 89

- systematic features 89
- therapy 133ff., 144
- treatment 1
- tuberculosis control 115ff.
- preventive therapy 7
- progress 7
- treatment of active TB 7
- strategic approaches 116, 117
- vaccination 6
- tuberculosis transmission dynamics
- mathematical modeling 227ff.
- tuberculosis-HIV co-infection
- approaches to developing improved treatments 215ff.
- goals for improving TB treatment 215
- treatment strategies 213ff.

#### **v**

- vaccination 6, 14, 24
- vaccine 1, 6, 56, 63, 115, 263
- variable numbers of tandem repeats (VNTR) 44ff., 70
- video-assisted thoracoscopy (VATS) 100

#### **w**

- World Health Organization (WHO) 1, 5ff., 23, 117, 134

#### **x**

- X-ray crystallography 145, 151
- X-ray screening 31

